{"id":"NCT00620022","sponsor":"Novartis","briefTitle":"The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2008-02-21","resultsPosted":"2011-08-17","lastUpdate":"2011-08-17"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Indacaterol 300 μg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Indacaterol 300 μg followed by placebo","type":"EXPERIMENTAL"},{"label":"Placebo followed by indacaterol 300 μg","type":"EXPERIMENTAL"}],"summary":"This study compared the effect of indacaterol (300 μg once daily \\[od\\]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.","primaryOutcome":{"measure":"Exercise Duration Time Assessed by Constant-load Cycle Ergometry at the End of Each Treatment Period","timeFrame":"End of each 3 week treatment period (last day of Weeks 3 and 9)","effectByArm":[{"arm":"Indacaterol 300 μg","deltaMin":586,"sd":30.3},{"arm":"Placebo","deltaMin":475,"sd":31.3}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":15},"locations":{"siteCount":20,"countries":["United States","Belgium","Canada","Denmark","Italy","Spain"]},"refs":{"pmids":["21498063"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":83},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease"]}}